SURPASS-2 and Tirzepatide: What the Trial Actually Showed

The biggest misconception: SURPASS-2 is not a weight-loss trial

Search results regularly present SURPASS-2 as headline evidence for tirzepatide's weight-loss effectiveness. That is an oversimplification. The trial was designed to assess glycaemic control (specifically HbA1c reduction) in adults already living with type 2 diabetes who had not achieved adequate control on metformin alone. Weight change was a secondary, not primary, endpoint. Every participant had diabetes. The semaglutide comparator was 1mg weekly, the standard diabetes dose at the time, not the 2.4mg dose approved later under the Wegovy licence for weight management.

This distinction is clinically important. Body-weight reductions recorded in SURPASS-2 reflect what happens in a diabetic population, who typically respond differently to GLP-1 and GIP receptor stimulation than people with obesity but without diabetes. Presenting those figures as equivalent to SURMOUNT-1 outcomes would be misleading. The trial was published in the New England Journal of Medicine in 2021 and remains a foundational paper in the tirzepatide story, just not quite the chapter people assume.

The broader SURPASS programme spans multiple studies across different populations and comparators. SURPASS-2 is one piece of that picture, and an important one, but reading it in isolation invites the wrong conclusions.

What SURPASS-2 actually found

Over 40 weeks, tirzepatide at all three doses (5mg, 10mg and 15mg) produced statistically greater reductions in HbA1c than semaglutide 1mg. Mean HbA1c fell by 2.01%, 2.24% and 2.30% respectively at the three doses, compared with 1.86% for semaglutide 1mg. Average body weight fell by around 7.8kg, 9.3kg and 11.2kg across the tirzepatide arms, versus around 5.7kg with semaglutide 1mg, a meaningful difference, though in a diabetic population over a shorter timeframe than SURMOUNT.

Side effects followed the pattern seen across the tirzepatide programme: gastrointestinal events were the most common, including nausea, diarrhoea and vomiting, with higher rates at the 10mg and 15mg doses and more common in the first weeks of treatment. The NHS tirzepatide medicines page summarises the side-effect profile in plain language for anyone starting to look into this treatment.

The trial also confirmed that tirzepatide's dual mechanism (stimulating both GIP and GLP-1 receptors) translated to real clinical differences, not just theoretical ones. That finding fed directly into the evidence base that supported UK licensing and the parallel SURPASS-1 data on dose-response.

How SURPASS-2 connects to tirzepatide's weight-management licence

The UK licence for tirzepatide in weight management rests primarily on the SURMOUNT programme, not SURPASS. NICE's appraisal of tirzepatide (TA1026), published in December 2024, drew on SURMOUNT-1 and SURMOUNT-2, which studied adults with obesity or overweight without diabetes. SURMOUNT-1 alone enrolled 2,539 participants, a scale that gives the evidence substantial weight.

SURPASS-2's contribution is contextual: it demonstrated that tirzepatide worked better than an established diabetes medicine on the outcomes that matter to people with type 2 diabetes. For someone who has both obesity and type 2 diabetes, the SURPASS data and the SURMOUNT data together present a coherent picture. A prescriber assessing suitability would consider both.

If you are exploring tirzepatide for weight management, the more directly relevant evidence is in the SURMOUNT programme. Our page on SURPASS-1 covers what the first SURPASS study added, and the SURPASS-3 data extends into longer-duration comparisons. For context on what tirzepatide typically costs privately in the UK, the Mounjaro pricing page sets out the market picture honestly. The full clinical picture across all the trials is summarised on our SURPASS study overview.

Some people ask whether SURPASS-2 means tirzepatide is 'better than Ozempic'. It is a reasonable question, and the honest answer is that SURPASS-2 compared the wrong doses for that conclusion. The head-to-head trial that answers it more directly is SURMOUNT-5, which compared tirzepatide against semaglutide 2.4mg in people with obesity. That is a different study with a different answer.

What this means if you are considering treatment

Tirzepatide is licensed in the UK as Mounjaro for weight management, and the evidence behind that licence is substantial, though the SURPASS programme tells the diabetes part of the story, not the whole one. If you have type 2 diabetes alongside obesity, the SURPASS findings are directly relevant to you; if you have obesity without diabetes, SURMOUNT-1 and SURMOUNT-2 are the trials to understand. Our Mounjaro overview covers both contexts without conflating them.

A word on timing: if you are thinking about starting and want treatment in place before a holiday or around a busy period, ordering by 12pm on a working day means our prescribers review your consultation that day and, if it is clinically appropriate, the pen is dispatched for next-working-day delivery. Christmas, bank holidays and payday Friday rushes are worth planning around, the process itself is fast, but planning early removes the stress.

These medicines are prescription-only. A real clinician reads every consultation, not software, not a checklist. If you want to explore whether tirzepatide is right for you, speak to our prescribers through a free consultation; there is no obligation and no hidden fees.